Conduct research and development of novel pharmaceutical products. Manufacture a range of pharmaceutical products for various therapeutic areas. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
An average decline of 60% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
At this burn rate the cash pile isn’t the pressing question — for now, time is on the company’s side.
This company is not turning a profit, so the market is pricing its sales instead: 4,299× for every dollar of annual revenue.
No analyst target is on record for this company.
The stock trades 52% below its peak. The market has trimmed its expectations for the company.
Sales run at $295K a year. A small number, but proof the product has real buyers.
There is $284.0M in the vault; even if every debt were paid off, $283.2M would remain.
A loss of $52.3M against $295K in annual sales.
Since the drop from its peak, buyer appetite hasn’t come back.
Costs swallow the gains that sales growth brings in.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: the revenue breakdown.